[Progress on medical treatment in the management of adenomyosis].

Baboo KD, Kalianee Devi Baboo, Chen Z, Zhengyun Chen, Xinmei Zhang, Zhang X
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2019 · vol. 48(2) , pp. 142–147 · doi:10.3785/j.issn.1008-9292.2019.04.04 · PMID:31309751 · PMC8800645 · W2983807439
article OA: green CC0 ⤵ 4 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Non-steroidal anti-inflammatory drugs, steroid hormones, GnRH agonists, and mifepristone manage adenomyosis symptoms, with drug choice depending on patient factors, though recurrence after withdrawal necessitates further study.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This paper reviews progress in medical treatment approaches for adenomyosis, surveying the types of pharmacologic options used and their roles in management. It synthesizes available evidence rather than reporting new experimental or clinical trial data, and the main limitation is that the paper’s conclusions depend on the scope and quality of previously published studies, which are summarized without presenting original endpoints. The review emphasizes how medical therapies have evolved for adenomyosis while acknowledging the need to interpret findings within the limitations of the existing literature. This paper is centrally about adenomyosis — it focuses on progress and developments in the medical treatment of adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Drug therapy plays an important role in alleviating the symptoms related to adenomyosis, improving the curative effect of surgery, delaying the progress of disease and promoting assisted reproduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice to control pain associated with adenomyosis, and are the only choice for patients with recent fertility requirements; steroid hormones, gonadotropin releasing hormone agonists and mifepristone can effectively relieve pain and control uterine bleeding, among which oral contraceptives, levonorgestrel-releasing intranterine system (Mirena) and dienogest are more effective and commonly used in clinic. Drug selection should be based on patient's age, symptoms, uterine size, fertility requirements and economical conditions. At present, there is no specific drug for adenomyosis, and symptoms are easy to recur after drug withdrawal, so the long-term drug use needs further study.
Full text 1,389 characters · extracted from oa-doi-fallback · click to expand
× SciEngine Journals & Books JOURNALS BOOKS CART CUSTOMER 中文 LOGIN Search SciEngine AI Intelligent Search Advanced Search LOG IN TO SciEngine Account Login Get verification code Forget the password Get code Sign in Register reset password Reset password link has been sent to your mailbox. Please check it in the mailbox. Print ISSN : 1008-9292 Online ISSN : 2097-5171 CN : 33-1248/R Open Access Content Menus Advanced Search Home Browse Latest Issue Archive Author Center Ethical Guidelines Scopes & Requirement for Submission Instructions to Authors Download Center Editorial Board About About Journal Journal policies Open Access Copyright and Licensing Contact us News Editorial Notice Home Browse Latest Issue Archive Author Center Ethical Guidelines Scopes & Requirement for Submission Instructions to Authors Download Center Editorial Board About About Journal Journal policies Open Access Copyright and Licensing Contact us News Editorial Notice Advanced Search × Add new Menu Name English Chinese URL Sort Jump Way _self _blank × Update Menu Name English Chinese URL Sort Jump Way _self _blank {{lang == 'en_US' ? 'This article has been Discontinue.' : '该文章已下架。'}} BACK TO TOP TOP × Company Info Chinese Company Info Integrated Info Register System Info Waiting... Interesting search NetworkPositioning Search results View all results from this journal/book Top 5 Related Articles

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Disease Management Female Humans Recurrence

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (4)

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:41.077124+00:00
License: CC0 · commercial use OK